Sector News

AGC Asahi Glass agrees to acquire CMC Biologics

December 21, 2016
Chemical Value Chain

CMC Biologics and AGC Asahi Glass announced today that they have entered into a definitive agreement with CMC Biologics’ shareholders, by which AGC will acquire 100% of CMC Biologics’ shares. This acquisition is expected to close in January 2017.

CMC Biologics is a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins. AGC Asahi Glass is a world-leading manufacturer of glass, chemicals and high-tech materials.

Founded in Denmark in 2001, as a start-up company, CMC Biologics has grown to be one of the most valued independent CDMO companies in the world. Today with over 500 employees, two commercial-phase manufacturing facilities, and one early-phase manufacturing facility, CMC is one of the leaders in the biologics CDMO industry.

“With the high level of growth and success that CMC Biologics has had over the last 15 years, I am thrilled that we now will be a central part of AGC’s pharmaceutical services business, with biologic manufacturing operations in Europe, U.S.A., and Asia. AGC is a world-class company dedicated to excellence and high customer satisfaction,” said David Kauffmann, Chairman of CMC Biologics. “AGC’s commitment to best technology solutions and longtime partnership with clients align so well with CMC Biologics’ mission to be the preferred biologics CDMO service partner for the world’s top pharmaceutical and biotech companies.”

“Aligning with AGC’s success and long-term business strategy, CMC Biologics is honored to become part of AGC’s Life Science Business. We look forward to leveraging on AGC’s manufacturing expertise and existing CMO footprint, while continuing to provide innovative solutions to our clients,” said Gustavo Mahler, Chief Executive Officer of CMC Biologics. “This transaction provides the ideal ownership for CMC, as AGC fully embraces the goals of customer satisfaction, strong growth and global expansion that define our strategy.”

CMC Biologics will retain its distinct brand and independence. There are no anticipated changes in CMC operations, current leadership team or employee base. CMC Biologics continues to be fully committed to delivering the best solutions for our customers.

Source: CMC Biologics

comments closed

Related News

May 15, 2022

New York’s EPR and packaging reduction bills lauded as game-changers in plastic pollution battle

Chemical Value Chain

The US State of New York is introducing two new bills to combat over-packaging, poor recycling rates and litter issues, including an Extended Producer Responsibility (EPR) program requiring companies such as McDonald’s and Amazon to pay for the cost of packaging disposal and recycling.

May 15, 2022

Borealis and Reclay launch entity focused on lightweight packaging 

Chemical Value Chain

The new organization’s mission is to redesign the critical steps of the plastics sorting and recycling system for post-consumer lightweight packaging (LWP) to speed up circularity, born from a need to meet the rising market demand for high-quality recyclates for use in high-end plastic applications.

May 15, 2022

Starbucks and Hubbub launch reusable packaging fund as COVID-19 diminishes consumer appetite

Chemical Value Chain

Starbucks and Hubbub have launched a £1 million (US$1.22 million) “Bring It Back Fund” to increase the uptake of reusable packaging in the F&B industry. The funding will go toward innovative ideas that make it easier for customers to use alternatives to single-use packaging by supporting pilot projects that help shift consumption habits.